enGene Holdings Inc. Reports $29.8 Million Net Loss and Increased Operating Expenses

enGene Holdings Inc. reported a net loss of $29.8 million for the three months ending January 31, 2026, compared to a loss of $24.6 million for the same period in 2025. The increase in net loss is attributed to higher operating expenses, which rose to $31.2 million from $26.6 million year-over-year. Research and development expenses accounted for a significant portion of this increase, totaling $22.3 million, up from $20.0 million, driven primarily by increased personnel-related costs and clinical operations associated with the ongoing LEGEND study of the company's lead product candidate, detalimogene voraplasmid.

The company’s total assets increased to $337.1 million as of January 31, 2026, up from $221.5 million at the end of the previous fiscal year. This growth was largely due to a significant rise in marketable securities, which increased to $275.9 million from $152.1 million. Cash and cash equivalents decreased to $36.6 million from $50.2 million, reflecting the company's ongoing investment in research and development activities. The accumulated deficit also widened to $401.8 million from $372.0 million, indicating the company's continued reliance on external financing to support its operations.

In terms of strategic developments, enGene completed a public offering in November 2025, raising approximately $130 million, which has bolstered its financial position. The company also entered into a Second Amended Loan Agreement with Hercules Capital, increasing its borrowing capacity to $125 million, contingent on achieving specific clinical milestones. This financing will support the ongoing clinical trials and potential commercialization efforts for detalimogene, which is currently being evaluated in a pivotal Phase 2 trial for treating non-muscle invasive bladder cancer.

Operationally, enGene has made progress in its clinical trials, with the pivotal cohort of the LEGEND study fully enrolled with 125 patients. The company is also exploring additional patient populations for detalimogene, which could expand its market potential. As of January 31, 2026, enGene had 66.99 million common shares outstanding, reflecting an increase from 52.02 million shares at the end of the previous fiscal year, primarily due to the public offering.

Looking ahead, enGene anticipates continued operating losses as it advances its clinical programs and prepares for a Biologics License Application submission to the FDA in the second half of 2026. The company expects that its existing cash and marketable securities will be sufficient to fund its operations for at least the next 12 months, but it acknowledges the need for additional funding to support its growth strategy and ongoing research and development activities.